Trial Outcomes & Findings for Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) (NCT NCT04544995)

Last Updated: 2026-01-21

Results Overview

DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.

Recruitment status

TERMINATED

Study phase

PHASE1

Target enrollment

47 participants

Primary outcome timeframe

Up to 42 days

Results posted on

2026-01-21

Participant Flow

This study was performed in two parts: Part 1: Dose Escalation and Part 2: Safety Run-in and Cohort Expansion.

Participant milestones

Participant milestones
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (age-based dose) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.	Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) Paediatric participants with recurrent or refractory osteosarcoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) Paediatric participants with recurrent or refractory neuroblastoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory osteosarcoma or neuroblastoma received niraparib (dose based on weight) tablet for oral suspension (TfOS) orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.
Overall Study STARTED	11	7	5	3	11	7	3
Overall Study DLT-Evaluable Population	8	6	2	2	0	0	3
Overall Study Intent-to-Treat (ITT) Population	11	6	5	3	0	0	3
Overall Study Modified Intent-to-Treat (mITT) Population	0	0	0	0	9	8	0
Overall Study Pharmacokinetic (PK) Population	11	7	5	3	11	7	3
Overall Study COMPLETED	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	11	7	5	3	11	7	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (age-based dose) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.	Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) Paediatric participants with recurrent or refractory osteosarcoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) Paediatric participants with recurrent or refractory neuroblastoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory osteosarcoma or neuroblastoma received niraparib (dose based on weight) tablet for oral suspension (TfOS) orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.
Overall Study Death	7	3	3	3	1	2	1
Overall Study Lost to Follow-up	0	0	0	0	1	0	0
Overall Study Physician Decision	0	0	0	0	5	0	0
Overall Study Withdrawal by Subject	0	0	0	0	0	1	0
Overall Study Study Terminated by Sponsor	1	0	0	0	0	0	1
Overall Study Reached protocol-defined stopping criteria	3	4	2	0	4	4	1

Baseline Characteristics

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.	Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) n=11 Participants Paediatric participants with recurrent or refractory osteosarcoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) n=7 Participants Paediatric participants with recurrent or refractory neuroblastoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory osteosarcoma or neuroblastoma received niraparib (dose based on weight) tablet for oral suspension (TfOS) orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Total n=47 Participants Total of all reporting groups
Sex: Female, Male Female	1 Participants n=37 Participants	5 Participants n=44 Participants	3 Participants n=40 Participants	3 Participants n=121 Participants	5 Participants n=24 Participants	3 Participants n=6 Participants	2 Participants n=33 Participants	22 Participants n=4 Participants
Sex: Female, Male Male	10 Participants n=37 Participants	2 Participants n=44 Participants	2 Participants n=40 Participants	0 Participants n=121 Participants	6 Participants n=24 Participants	4 Participants n=6 Participants	1 Participants n=33 Participants	25 Participants n=4 Participants
Age, Continuous	13.9 YEARS STANDARD_DEVIATION 2.84 • n=37 Participants	13.7 YEARS STANDARD_DEVIATION 3.99 • n=44 Participants	13.0 YEARS STANDARD_DEVIATION 3.81 • n=40 Participants	6.0 YEARS STANDARD_DEVIATION 1.00 • n=121 Participants	14.3 YEARS STANDARD_DEVIATION 2.45 • n=24 Participants	10.1 YEARS STANDARD_DEVIATION 2.97 • n=6 Participants	14.7 YEARS STANDARD_DEVIATION 1.53 • n=33 Participants	12.9 YEARS STANDARD_DEVIATION 3.50 • n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=37 Participants	0 Participants n=44 Participants	0 Participants n=40 Participants	0 Participants n=121 Participants	0 Participants n=24 Participants	0 Participants n=6 Participants	0 Participants n=33 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Asian	0 Participants n=37 Participants	0 Participants n=44 Participants	0 Participants n=40 Participants	0 Participants n=121 Participants	1 Participants n=24 Participants	2 Participants n=6 Participants	0 Participants n=33 Participants	3 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=37 Participants	0 Participants n=44 Participants	0 Participants n=40 Participants	0 Participants n=121 Participants	0 Participants n=24 Participants	0 Participants n=6 Participants	0 Participants n=33 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Black or African American	0 Participants n=37 Participants	0 Participants n=44 Participants	0 Participants n=40 Participants	0 Participants n=121 Participants	1 Participants n=24 Participants	0 Participants n=6 Participants	0 Participants n=33 Participants	1 Participants n=4 Participants
Race (NIH/OMB) White	11 Participants n=37 Participants	7 Participants n=44 Participants	5 Participants n=40 Participants	3 Participants n=121 Participants	9 Participants n=24 Participants	5 Participants n=6 Participants	3 Participants n=33 Participants	43 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=37 Participants	0 Participants n=44 Participants	0 Participants n=40 Participants	0 Participants n=121 Participants	0 Participants n=24 Participants	0 Participants n=6 Participants	0 Participants n=33 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=37 Participants	0 Participants n=44 Participants	0 Participants n=40 Participants	0 Participants n=121 Participants	0 Participants n=24 Participants	0 Participants n=6 Participants	0 Participants n=33 Participants	0 Participants n=4 Participants

PRIMARY outcome

Timeframe: Up to 42 days

Population: DLT-evaluable population consists of participants in Part 1 who completed the DLT observation period through at least 2 cycles of study treatment (including ≥80% of the intended niraparib dose and ≥2 infusions of dostarlimab) or experienced a DLT.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=8 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=6 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=2 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=2 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Number of Participants With Dose-limiting Toxicities (DLT)	1 Participants	1 Participants	2 Participants	2 Participants

PRIMARY outcome

Timeframe: Up to 42 days

Population: DLT-evaluable Population consists of participants in Part 2 Safety Run-in who completed the DLT observation period through at least 2 cycles of study treatment (including ≥80% of the intended niraparib dose and ≥2 infusions of dostarlimab) or experienced a DLT.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Number of Participants With Dose-limiting Toxicities (DLT)	1 Participants	—	—	—

PRIMARY outcome

Timeframe: Up to 42 days

Thrombocytopenia events were defined as treatment-related toxicities of Grade 3 or Grade 4 thrombocytopenia occurring within the first 42 days of study treatment. AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Number of Participants With Grade ≥3 Thrombocytopenia Adverse Events	0 Participants	—	—	—

PRIMARY outcome

Timeframe: At Month 6

Population: Modified Intent-to-treat (mITT) population for Part 2A Osteosarcoma cohort included participants who received any study medication, had measurable baseline tumour assessment, and had at least 1 post-baseline tumour assessment. Data from 1 participant treated in Part 1A Cohort 1A at the same dose level as 8 participants treated in Part 2A were pooled and analyzed collectively for this outcome measure.

PFS6 is defined as the percentage of participants without progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death at 6 months from the date of the first dose of study treatment. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=9 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Progression-Free Survival at 6 Months Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1	0 Percentage of Participants Interval 0.0 to 33.6	—	—	—

PRIMARY outcome

Timeframe: Up to approximately 196 weeks

Population: Modified Intent-to-treat (mITT) population for Part 2B Neuroblastoma cohort included participants who received any study medication, had measurable baseline tumour assessment and/or MIBG-positive disease (or FDG-positive disease, for MIBG-nonavid tumours) at baseline, and had at least 1 post-baseline tumour assessment. Data from 2 participants treated in Part 1A Cohort 1A at the same dose level as 6 participants treated in Part 2B were pooled and analyzed collectively for this outcome measure.

ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using International Neuroblastoma Response Criteria (INRC). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=8 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Objective Response Rate (ORR) by the Investigator Using International Neuroblastoma Response Criteria (INRC)	0 Percentage of Participants Interval 0.0 to 36.9	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: ITT Population included all participants who received any study medication and had measurable baseline tumour assessment and/or, for neuroblastoma participants, MIBG-positive disease (or FDG-positive disease, for MIBG-nonavid tumours) at baseline.

ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR using RECIST v1.1 or INRC (for neuroblastoma participants only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=6 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Objective Response Rate (ORR)	9 Percentage of Participants Interval 0.2 to 41.3	0 Percentage of Participants Interval 0.0 to 45.9	0 Percentage of Participants Interval 0.0 to 52.2	0 Percentage of Participants Interval 0.0 to 70.8

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: ITT population. Only responders (CR or PR) by investigator assessment were included in this analysis.

DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=1 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Duration of Response (DOR)	37.29 Months Full range is not applicable as only a single participant was analyzed.	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population is defined as all participants who received at least 1 dose of either niraparib or dostarlimab.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) TEAEs	11 Participants	7 Participants	5 Participants	3 Participants
Part 1A and Part 1B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) SAEs	6 Participants	2 Participants	2 Participants	2 Participants

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)	2 Participants	5 Participants	0 Participants	2 Participants

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation TEAEs leading to Death	3 Participants	1 Participants	0 Participants	0 Participants
Part 1A and Part 1B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation Treatment Discontinuation	3 Participants	1 Participants	1 Participants	2 Participants

SECONDARY outcome

Timeframe: 2.5 hours (HR) and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2

Population: Pharmacokinetic (PK) population included all participants who received at least one dose of study treatment and had at least one PK sample. Only those participants with data available at specified data points have been analyzed.

Blood samples were obtained to analyze niraparib concentration levels.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Niraparib Concentrations Cycle 1 Week 2, 168 HR post-dose	419.255 nanogram/ millilitre (ng/mL) Standard Deviation 203.6362	396.286 nanogram/ millilitre (ng/mL) Standard Deviation 276.8006	812.000 nanogram/ millilitre (ng/mL) Standard Deviation 704.5534	887.667 nanogram/ millilitre (ng/mL) Standard Deviation 628.3664
Part 1A and Part 1B: Niraparib Concentrations Cycle 1 Week 1, 2.5 HR post-dose	120.045 nanogram/ millilitre (ng/mL) Standard Deviation 198.6774	44.300 nanogram/ millilitre (ng/mL) Standard Deviation 58.0753	83.480 nanogram/ millilitre (ng/mL) Standard Deviation 107.4614	383.900 nanogram/ millilitre (ng/mL) Standard Deviation 413.0918
Part 1A and Part 1B: Niraparib Concentrations Cycle 1 Week 1, 7 HR post-dose	347.889 nanogram/ millilitre (ng/mL) Standard Deviation 133.9846	254.571 nanogram/ millilitre (ng/mL) Standard Deviation 141.7096	640.200 nanogram/ millilitre (ng/mL) Standard Deviation 449.5850	522.500 nanogram/ millilitre (ng/mL) Standard Deviation 369.8168

SECONDARY outcome

Timeframe: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose) on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4, 6, 12, 18, 24, 30, 36; End of Treatment (Up to approximately 196 weeks)

Population: PK population. The number analyzed for each timepoint reflects the number of participants from the Overall PK population with a non-missing value at the specified time point. Rows and Arms/Groups with 0 participants analyzed represent time points at which no participant data was available from within the respective Arms/Groups.

Blood samples were collected for PK analysis of Dostarlimab.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 4 Week 1, Pre-dose	23.100 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	81.400 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 6 Week 1, Pre-dose	25.100 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	103.000 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 12 Week 1, Pre-dose	21.400 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	58.400 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 36 Week 1, Pre-dose	33.500 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—	—
Part 1A and Part 1B: Dostarlimab Concentrations End of Treatment, End of Treatment	16.543 milligram/ litre (mg/L) Standard Deviation 8.6016	58.700 milligram/ litre (mg/L) Standard Deviation 47.2811	16.507 milligram/ litre (mg/L) Standard Deviation 13.6358	46.800 milligram/ litre (mg/L) Standard Deviation 40.5879
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 1 Week 1, Day 1 pre-dose	0.000 milligram/ litre (mg/L) Standard Deviation 0.0000	0.000 milligram/ litre (mg/L) Standard Deviation 0.0000	0.000 milligram/ litre (mg/L) Standard Deviation 0.0000	0.000 milligram/ litre (mg/L) Standard Deviation 0.0000
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 1 Week 1, 1 hr post-dose	58.291 milligram/ litre (mg/L) Standard Deviation 10.7135	124.743 milligram/ litre (mg/L) Standard Deviation 30.9267	69.720 milligram/ litre (mg/L) Standard Deviation 9.8228	129.000 milligram/ litre (mg/L) Standard Deviation 2.6458
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 1 Week 2, 168 hrs post-dose	21.045 milligram/ litre (mg/L) Standard Deviation 4.5276	55.314 milligram/ litre (mg/L) Standard Deviation 10.1568	28.660 milligram/ litre (mg/L) Standard Deviation 14.1661	55.600 milligram/ litre (mg/L) Standard Deviation 8.2286
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 18 Week 1, Pre-dose	21.200 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	60.900 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 24 Week 1, Pre-dose	12.400 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—	—
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 30 Week 1, Pre-dose	33.800 milligram/ litre (mg/L) Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—	—
Part 1A and Part 1B: Dostarlimab Concentrations Cycle 2 Week 1, 504 hrs post-dose	12.256 milligram/ litre (mg/L) Standard Deviation 2.1518	35.100 milligram/ litre (mg/L) Standard Deviation 11.1095	13.240 milligram/ litre (mg/L) Standard Deviation 5.0411	43.000 milligram/ litre (mg/L) Standard Deviation 7.4953

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Immunogenicity (ADA) Population included all participants who received at least 1 dose of dostarlimab and who had at least 1 ADA sample with a result.

Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: At Week 1 of Cycle 1

Population: Safety Population

The acceptability and palatability for participants who received niraparib tablet or TfOS were evaluated by using a questionnaire.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 Participants Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 Participants Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 1A and Part 1B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires	11 Participants	7 Participants	5 Participants	2 Participants

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Intent-to-treat population included all participants who received any study medication and had measurable baseline tumour assessment.

ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR, using RECIST v1.1 or INRC (neuroblastoma only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Objective Response Rate (ORR)	0 Percentage of Participants No participants achieved confirmed CR or PR	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: ITT population. Only responders (CR or PR) by investigator assessment were included in this analysis.

DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). It is calculated for participants with a BOR of confirmed CR or PR. If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: ITT population

DCR is the percentage of participants achieving a BOR of confirmed CR, PR, or stable disease (SD) by RECIST v1.1 or INRC (neuroblastoma only). Per RECIST v1.1: CR is disappearance of all target lesions and pathological lymph nodes \<10 mm in short axis; PR is ≥30% decrease in lesion diameters from baseline; SD is neither sufficient shrinkage for PR nor sufficient increase for PD. Per INRC: CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Disease Control Rate (DCR)	0 Percentage of Participants No participants with confirmed CR, PR or stable disease	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: ITT population

PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 or INRC (in participants with neuroblastoma only) based on Investigator assessment, or death from any cause (whichever occurs first). Per RECISTv1.1: PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Per INRC: PD is \>20% lesion size increase, new lesions, or increased marrow tumor infiltration (\>5%).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Progression-free Survival (PFS)	1.68 Months Interval 1.35 to 2.0	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) TEAEs	3 Participants	—	—	—
Part 2 Safety-run in: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) SAEs	2 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)	2 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation Leading to Death	0 Participants	—	—	—
Part 2 Safety-run in: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation Treatment Discontinuation	2 Participants	—	—	—

SECONDARY outcome

Timeframe: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, Pre-dose on Cycle 1 Week 2 and Pre-dose and 5 HR post-dose on Cycle 2 Week 1

Population: PK population. Only those participants with data available at specified data points have been analyzed.

Blood samples were obtained to analyze niraparib concentration levels.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=3 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2 Safety-run in: Niraparib Concentrations Cycle 1 Week 1, 2.5 HR post-dose	109.000 ng/mL Standard Deviation 121.7060	—	—	—
Part 2 Safety-run in: Niraparib Concentrations Cycle 1 Week 1, 7 HR post-dose	292.067 ng/mL Standard Deviation 225.1404	—	—	—
Part 2 Safety-run in: Niraparib Concentrations Cycle 1 Week 2, Pre-dose	329.200 ng/mL Standard Deviation 272.7140	—	—	—
Part 2 Safety-run in: Niraparib Concentrations Cycle 2 Week 1, Pre-dose	338.667 ng/mL Standard Deviation 253.1291	—	—	—
Part 2 Safety-run in: Niraparib Concentrations Cycle 2 Week 1, 5 HR post-dose	834.667 ng/mL Standard Deviation 612.8428	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Modified Intent-to-treat (mITT) population for Osteosarcoma cohort. Only those participants at specified timepoint have been anaysed. Data from 1 participant treated in Part 1A Cohort 1A at the same dose level as 8 participants treated in Part 2A were pooled and analyzed collectively for this outcome measure.

ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1. CR was defined as disappearance of all target and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=9 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Objective Response Rate (ORR) by the Investigator Using RECIST v1.1	0 Percentage of Participants Interval 0.0 to 33.6	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Modified Intent-to-treat (mITT) population for Osteosarcoma cohort. Only responders (CR or PR) by investigator assessment were included in this analysis.

DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by RECIST v1.1 , based on Investigator assessment, or death (whichever occurs first). CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Modified Intent-to-treat (mITT) population for Part 2A Osteosarcoma cohort. Data from 1 participant treated in Part 1A Cohort 1A at the same dose level as 8 participants treated in Part 2A were pooled and analyzed collectively for this outcome measure.

DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) by RECIST v1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=9 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Disease Control Rate (DCR) by the Investigator Using RECIST v1.1	0 Percentage of Participants Interval 0.0 to 33.6	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 , based on Investigator assessment, or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=9 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Progression-free Survival (PFS) by the Investigator Using RECIST v1.1	1.2 Months Interval 0.7 to 2.1	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Number of Participants With of Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) SAEs	4 Participants	—	—	—
Part 2A: Number of Participants With of Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) TEAEs	11 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)	2 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation Leading to Death	0 Participants	—	—	—
Part 2A: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation Treatment Discontinuation	2 Participants	—	—	—

SECONDARY outcome

Timeframe: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2

Population: PK population. Only those participants with data available at specified data points have been analyzed.

Blood samples were obtained to analyze niraparib concentration levels.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Niraparib Concentrations Cycle 1 Week 1, 2.5 HR post-dose	217.212 ng/mL Standard Deviation 236.5667	—	—	—
Part 2A: Niraparib Concentrations Cycle 1 Week 1, 7 HR post-dose	241.482 ng/mL Standard Deviation 143.3515	—	—	—
Part 2A: Niraparib Concentrations Cycle 1 Week 2, 168 HR post-dose	354.100 ng/mL Standard Deviation 153.7909	—	—	—

SECONDARY outcome

Timeframe: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose) on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4 and 6; End of Treatment (Up to approximately 196 weeks)

Population: PK population. Only those participants with data available at specified data points have been analyzed.

Blood samples were collected for PK analysis of Dostarlimab.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Dostarlimab Concentrations Cycle 1 Week 1, Day 1 pre-dose	0.000 mg/L Standard Deviation 0.0000	—	—	—
Part 2A: Dostarlimab Concentrations Cycle 1 Week 1, 1 hr post-dose	135.509 mg/L Standard Deviation 45.2007	—	—	—
Part 2A: Dostarlimab Concentrations Cycle 1 Week 2, 168 hrs post-dose	65.022 mg/L Standard Deviation 8.6129	—	—	—
Part 2A: Dostarlimab Concentrations Cycle 2 Week 1, 504 hrs post-dose	45.000 mg/L Standard Deviation 27.4571	—	—	—
Part 2A: Dostarlimab Concentrations Cycle 4 Week 1, Pre-dose	46.900 mg/L Standard Deviation 23.0517	—	—	—
Part 2A: Dostarlimab Concentrations Cycle 6 Week 1, Pre-dose	133.000 mg/L Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—	—
Part 2A: Dostarlimab Concentrations End of Treatment, End of Treatment	74.338 mg/L Standard Deviation 52.2281	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: ADA Population

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=10 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab	0 Participants	—	—	—

SECONDARY outcome

Timeframe: At Week 1 of Cycle 1

Population: Safety Population

The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2A: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires	11 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Modified Intent-to-treat (mITT) population for Part 2B Neuroblastoma cohort. Only responders (CR or PR) by investigator assessment were included in this analysis.

DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by INRC , based on Investigator assessment, or death (whichever occurs first). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%. PD is \>20% lesion size increase,new lesions or increased tumor infiltration in bone marrow.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Modified Intent-to-treat (mITT) population for Part 2B Neuroblastoma cohort. Data from 2 participants treated in Part 1A Cohort 1A at the same dose level as 6 participants treated in Part 2B were pooled and analyzed collectively for this outcome measure.

DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or SD by INRC. CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=8 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Disease Control Rate (DCR) by the Investigator by INRC	38 Percentage of Participants Interval 8.5 to 75.5	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by INRC , based on Investigator assessment, or death (whichever occurs first). PD is \>20% lesion size increase, new lesions, or increased tumor infiltration in bone marrow.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=8 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Progression-free Survival (PFS) by the Investigator by INRC	2.9 Months Interval 0.5 to 10.2	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety population

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) TEAEs	7 Participants	—	—	—
Part 2B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) SAEs	4 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety population

Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)	4 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: Safety Population

A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation Leading to Death	0 Participants	—	—	—
Part 2B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation Treatment Discontinuation	3 Participants	—	—	—

SECONDARY outcome

Timeframe: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2

Population: PK population. Only those participants with data available at specified data points have been analyzed.

Blood samples were obtained to analyze niraparib concentration levels.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Niraparib Concentrations Cycle 1 Week 1, 7 HR post-dose	329.571 ng/mL Standard Deviation 182.8432	—	—	—
Part 2B: Niraparib Concentrations Cycle 1 Week 2, 168 HR post-dose	700.143 ng/mL Standard Deviation 571.6900	—	—	—
Part 2B: Niraparib Concentrations Cycle 1 Week 1, 2.5 HR post-dose	275.600 ng/mL Standard Deviation 330.9424	—	—	—

SECONDARY outcome

Timeframe: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4, 6, 12 and 18; End of Treatment (Up to approximately 196 weeks)

Population: PK population. Only those participants with data available at specified data points have been analyzed.

Blood samples were collected for PK analysis of Dostarlimab.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Dostarlimab Concentrations Cycle 1 Week 1, Day 1 pre-dose	0.000 mg/L Standard Deviation 0.0000	—	—	—
Part 2B: Dostarlimab Concentrations Cycle 1 Week 1, 1 hr post-dose	186.000 mg/L Standard Deviation 117.4748	—	—	—
Part 2B: Dostarlimab Concentrations Cycle 1 Week 2, 168 hrs post-dose	61.943 mg/L Standard Deviation 13.5405	—	—	—
Part 2B: Dostarlimab Concentrations Cycle 2 Week 1, 504 hrs post-dose	39.925 mg/L Standard Deviation 13.4205	—	—	—
Part 2B: Dostarlimab Concentrations Cycle 4 Week 1, Pre-dose	88.500 mg/L Standard Deviation 22.3900	—	—	—
Part 2B: Dostarlimab Concentrations Cycle 6 Week 1, Pre-dose	173.667 mg/L Standard Deviation 90.4231	—	—	—
Part 2B: Dostarlimab Concentrations Cycle 12 Week 1, Pre-dose	179.500 mg/L Standard Deviation 24.7487	—	—	—
Part 2B: Dostarlimab Concentrations Cycle 18 Week 1, Pre-dose	121.000 mg/L Standard Deviation NA Standard deviation is not evaluable as only single participant was analyzed.	—	—	—
Part 2B: Dostarlimab Concentrations End of Treatment, End of Treatment	93.580 mg/L Standard Deviation 69.6794	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 196 weeks

Population: ADA Population

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab	0 Participants	—	—	—

SECONDARY outcome

Timeframe: At Week 1 of Cycle 1

Population: Safety Population

The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.

Outcome measures

Outcome measures
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=7 Participants Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.
Part 2B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires	7 Participants	—	—	—

Adverse Events

Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)

Serious events: 6 serious events

Other events: 11 other events

Deaths: 7 deaths

Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg

Serious events: 2 serious events

Other events: 7 other events

Deaths: 3 deaths

Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg

Serious events: 2 serious events

Other events: 5 other events

Deaths: 3 deaths

Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg

Serious events: 2 serious events

Other events: 3 other events

Deaths: 3 deaths

Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)

Serious events: 4 serious events

Other events: 11 other events

Deaths: 2 deaths

Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)

Serious events: 4 serious events

Other events: 7 other events

Deaths: 2 deaths

Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg

Serious events: 2 serious events

Other events: 3 other events

Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 participants at risk Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 participants at risk Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 participants at risk Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 participants at risk Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.	Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) n=11 participants at risk Paediatric participants with recurrent or refractory osteosarcoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) n=7 participants at risk Paediatric participants with recurrent or refractory neuroblastoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg n=3 participants at risk Paediatric participants with recurrent or refractory osteosarcoma or neuroblastoma received niraparib (dose based on weight) tablet for oral suspension (TfOS) orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.
Blood and lymphatic system disorders Anaemia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Immune thrombocytopenia	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Cardiac disorders Sinus tachycardia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Cardiac disorders Tachycardia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Abdominal pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Nausea	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Vomiting	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Chest pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Pyrexia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations COVID-19	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Alanine aminotransferase increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Aspartate aminotransferase increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Blood creatinine increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Platelet count decreased	9.1% 1/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Musculoskeletal and connective tissue disorders Pain in extremity	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Cerebral haemorrhage	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Headache	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Hypotonia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Immune-mediated encephalitis	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Lethargy	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Syncope	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Pleural effusion	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Respiratory disorder	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Respiratory failure	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.

Other adverse events

Other adverse events
Measure	Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) n=11 participants at risk Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, disease progression (PD), unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg n=7 participants at risk Paediatric participants with recurrent or refractory solid tumours received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg n=5 participants at risk Paediatric participants with recurrent or refractory solid tumours received 200 mg niraparib tablet orally once daily along with 3 mg/kg dostarlimab solution as a 30-minute IV infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg n=3 participants at risk Paediatric participants with recurrent or refractory solid tumours received niraparib (dose based on age) age-appropriate liquid formulation (AAOLF) orally once daily and 7.5 mg/kg dostarlimab as a 30-minute IV infusion before the niraparib dose on Day 1 of each 21-day cycle until the end of the Treatment Period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision, or death.	Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) n=11 participants at risk Paediatric participants with recurrent or refractory osteosarcoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) n=7 participants at risk Paediatric participants with recurrent or refractory neuroblastoma received 100 mg niraparib tablet orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.	Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg n=3 participants at risk Paediatric participants with recurrent or refractory osteosarcoma or neuroblastoma received niraparib (dose based on weight) tablet for oral suspension (TfOS) orally once daily along with 7.5 mg/kg dostarlimab solution as a 30-minute intravenous (IV) infusion prior to the niraparib dose on Day 1 of each 21-day treatment cycle until the end of treatment period, PD, unacceptable toxicity, withdrawal of consent/assent, investigator's decision to withdraw, or death.
Endocrine disorders Hypothyroidism	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Anaemia	63.6% 7/11 • Number of events 12 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	42.9% 3/7 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	40.0% 2/5 • Number of events 8 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	100.0% 3/3 • Number of events 6 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	27.3% 3/11 • Number of events 9 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	42.9% 3/7 • Number of events 8 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	66.7% 2/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Eosinophilia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Leukopenia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	40.0% 2/5 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	100.0% 3/3 • Number of events 8 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Lymph node pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Neutropenia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	66.7% 2/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Blood and lymphatic system disorders Thrombocytopenia	18.2% 2/11 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	40.0% 2/5 • Number of events 6 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	42.9% 3/7 • Number of events 9 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	66.7% 2/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Cardiac disorders Sinus tachycardia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Cardiac disorders Tachycardia	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Ear and labyrinth disorders Ear pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Ear and labyrinth disorders Vertigo	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Endocrine disorders Hyperthyroidism	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Eye disorders Dry eye	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Eye disorders Eye pruritus	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Eye disorders Eyelid ptosis	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Eye disorders Swelling of eyelid	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Eye disorders Vision blurred	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Abdominal pain	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	66.7% 2/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Abdominal pain upper	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Constipation	27.3% 3/11 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	60.0% 3/5 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Diarrhoea	9.1% 1/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Dyspepsia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Food poisoning	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Gastrooesophageal reflux disease	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Gingival bleeding	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Haematemesis	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Hypoaesthesia oral	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Lip dry	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Nausea	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	60.0% 3/5 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Odynophagia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Paraesthesia oral	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Stomatitis	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Toothache	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Gastrointestinal disorders Vomiting	27.3% 3/11 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	57.1% 4/7 • Number of events 7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	40.0% 2/5 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	27.3% 3/11 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	42.9% 3/7 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Asthenia	27.3% 3/11 • Number of events 7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Chest pain	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Fatigue	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Hyperthermia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Localised oedema	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Non-cardiac chest pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Oedema peripheral	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	66.7% 2/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Pyrexia	63.6% 7/11 • Number of events 13 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Swelling	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
General disorders Systemic inflammatory response syndrome	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Hepatobiliary disorders Hepatosplenomegaly	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Immune system disorders Seasonal allergy	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Bacteraemia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations COVID-19	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Escherichia urinary tract infection	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Gastroenteritis	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Gingivitis	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Herpes dermatitis	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Herpes simplex	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Herpes simplex reactivation	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Influenza	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Oral candidiasis	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Oral herpes	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Pneumonia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Upper respiratory tract infection	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Infections and infestations Urinary tract infection	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Injury, poisoning and procedural complications Contusion	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Alanine aminotransferase increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	57.1% 4/7 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	66.7% 2/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Amylase increased	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Aspartate aminotransferase increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	42.9% 3/7 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	66.7% 2/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	42.9% 3/7 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Bilirubin conjugated increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Blood alkaline phosphatase increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Dizziness	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Blood bilirubin increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Blood creatinine increased	9.1% 1/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Blood fibrinogen increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Blood thyroid stimulating hormone increased	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Blood urea increased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations C-reactive protein increased	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Gamma-glutamyltransferase increased	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Lipase increased	9.1% 1/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Lymphocyte count decreased	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Neutrophil count decreased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	40.0% 2/5 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	42.9% 3/7 • Number of events 7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Platelet count decreased	18.2% 2/11 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	66.7% 2/3 • Number of events 8 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Protein urine present	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Tri-iodothyronine increased	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations Weight decreased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations White blood cell count decreased	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Investigations White blood cells urine positive	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Decreased appetite	18.2% 2/11 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	27.3% 3/11 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	42.9% 3/7 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hyperglycaemia	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hypocalcaemia	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hyponatraemia	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Metabolism and nutrition disorders Hypophosphataemia	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Musculoskeletal and connective tissue disorders Back pain	27.3% 3/11 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	9.1% 1/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Musculoskeletal and connective tissue disorders Myalgia	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Musculoskeletal and connective tissue disorders Pain in extremity	18.2% 2/11 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	40.0% 2/5 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Melanocytic naevus	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Cerebral haemorrhage	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Dizziness postural	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Headache	18.2% 2/11 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Lethargy	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Neuralgia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Seizure	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Spinal cord compression	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Nervous system disorders Trigeminal neuralgia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Psychiatric disorders Agitation	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Psychiatric disorders Anxiety	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Psychiatric disorders Delirium	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Psychiatric disorders Depression	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Psychiatric disorders Insomnia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Psychiatric disorders Irritability	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Renal and urinary disorders Urine odour abnormal	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Reproductive system and breast disorders Pelvic pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Bronchospasm	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Cough	27.3% 3/11 • Number of events 7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	28.6% 2/7 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Dyspnoea	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Epistaxis	18.2% 2/11 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	20.0% 1/5 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Pleural effusion	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Respiratory disorder	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Skin and subcutaneous tissue disorders Drug eruption	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Respiratory, thoracic and mediastinal disorders Throat irritation	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Skin and subcutaneous tissue disorders Photosensitivity reaction	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	14.3% 1/7 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Skin and subcutaneous tissue disorders Purpura	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Skin and subcutaneous tissue disorders Rash	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	9.1% 1/11 • Number of events 1 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.
Vascular disorders Hypertension	0.00% 0/11 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/5 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/3 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	18.2% 2/11 • Number of events 2 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	0.00% 0/7 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.	33.3% 1/3 • Number of events 4 • All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks. The Safety Population included all participants who received at least 1 dose of either niraparib or dostarlimab.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER